Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAVIGATION Study
NCT05696548Phase 2Active, not recruiting
- Sponsor
- National Cancer Center Hospital East
- Start
- Jul 2019
- Primary completion
- Sep 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, lenvatinib in anaplastic thyroid cancer (ATC), sponsored by National Cancer Center Hospital East. Started Jul 2019; status: active, not recruiting.
02
Drugs
nivolumablenvatinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT05696548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05696548.